scholarly journals The Role of Hepatic Expression of STAT1, SOCS3 and PIAS1 in the Response of Chronic Hepatitis C Patients to Therapy

2013 ◽  
Vol 27 (2) ◽  
pp. e13-e17 ◽  
Author(s):  
Sherif El-Saadany ◽  
Dina H Ziada ◽  
Hanan El Bassat ◽  
Wael Farrag ◽  
Hesham El-Serogy ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Protein Expression ◽  
Western Blotting ◽  
Liver Tissue ◽  
Negative Regulators ◽  
Group 2 ◽  
Chronic Hcv ◽  
Socs3 Protein ◽  
Group 1 ◽  
Liver Tissues

BACKGROUND: The underlying mechanisms of hepatitis C virus (HCV) resistance to treatment are unknown. Signal transducers and activators of transcription (STAT) proteins play a critical role in antiviral defense.OBJECTIVE: To explore some of the mechanisms of HCV resistance to interferon, the expression of STAT1 and its negative regulators, protein inhibitor of activated STAT (PIAS1) and suppressor of cytokine signalling (SOCS3), in liver tissues of both inteferon responders and nonresponders in chronic HCV patients.METHODS: Sixty patients were divided into the following groups: group 1a comprised 38 treatment-responder chronic HCV patients; group 1b consisted of 22 treatment-nonresponder chronic HCV patients; and group 2 consisted of six control subjects. Liver biopsies were examined for histological scoring; STAT1, SOCS3 and PIAS1 expression was analyzed using Western blotting methods.RESULTS: STAT1 expression in the liver tissue of patients in group 1 was significantly increased compared with group 2 patients (P=0.001), while no significant difference in expression was observed between group 1a and group 1b patients (P=0.747). However, phosphorylated STAT1 protein was expressed at a significantly higher level in liver tissue of patients in group 1a compared with patients in group 1b (P=0.001). Western blot analysis of PIAS1 and SOCS3 protein expression in liver tissues from groups 1 and 2 revealed significantly increased expression in group 1 compared with group 2 (P=0.001). In addition, PIAS1 and SOCS3 protein expression was significantly higher in the liver tissues of patients in group 1b compared with patients in group 1a.CONCLUSION: Levels of STAT1 and/or the protein expression of its negative regulators, PIAS1 and SOCS3, may be a good predictor of response to therapy. These could be used as biomarkers that are easily detected by Western blotting or immunostaining during standard histopathological liver biopsy analysis.

Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology Clinic

2021 ◽  
pp. 001857872110375
Author(s):  
Frank A. Fanizza ◽  
Jennifer Loucks ◽  
Angelica Berni ◽  
Meera Shah ◽  
Dennis Grauer ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Medication Adherence ◽  
Hcv Treatment ◽  
Clinical Pharmacists ◽  
The Mean ◽  
Group 2 ◽  
Cure Rates ◽  
The Impact ◽  
Mean Time ◽  
Group 1

Background: Modern hepatitis C virus (HCV) treatment regimens yield cure rates greater than 90%. However, obtaining approval for treatment through the prior authorization (PA) process can be time consuming and require extensive documentation. Lack of experience with this complex process can delay HCV medication approval, ultimately increasing the amount of time before patients start treatment and in some cases, prevent treatment altogether. Objectives: Assess the impact of incorporating clinical pharmacists into specialty pharmacy and hepatology clinic services on medication access, patient adherence, and outcomes in patients being treated for HCV. Methods: We performed a retrospective cohort exploratory study of patients seen in an academic medical center hepatology clinic who had HCV prescriptions filled between 8/1/15 and 7/31/17. Patients were categorized by whether they filled prescriptions prior to (Pre-Group) or after (Post-Group) the implementation of a pharmacist in clinic. The Post-Group was further divided according to whether the patient was seen by a pharmacist in clinic (Post-Group 2) or if the patient was not seen by the pharmacist, but had their HCV therapy evaluated by the pharmacist before seeking insurance approval (Post-Group 1). Results: The mean time from the prescription being ordered to being dispensed was longer in the Pre-Group (50.8 ± 66.5 days) compared to both Post-Groups (22.2 ± 27.8 days in Post-Group 1 vs 18.9 ± 17.7 days in Post-Group 2; P < .05). The mean time from when the prescription was ordered to when the PA was submitted was longer in the Pre-Group (41.6 ± 71.9 days) compared to both Post-Groups (6.3 ± 16 in Post-Group 1 vs 4.1 ± 9.7 in Post-Group 2; P < .05). Rates of medication adherence and sustained virologic response were similar between all groups. Conclusion: Incorporation of clinical pharmacists into a hepatology clinic significantly reduced the time patients waited to start HCV treatment. In addition to improving access to medications, implementation of the model helped to maintain excellent medication adherence and cure rates.

Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness

2020 ◽  
Author(s):  
Nahed A Makhlouf ◽  
Mohamed O Abdelmalek ◽  
Mohamed Eltaher Ibrahim ◽  
Nagla H Abu-Faddan ◽  
Abeer E Kheila ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Stiffness ◽  
Hcv Rna ◽  
Genotype 4 ◽  
Hematological Disorders ◽  
Apri Score ◽  
Treatment Naïve ◽  
Patient Groups ◽  
Group 2 ◽  
Chronic Hcv

Abstract Background Egypt has the highest prevalence of hepatitis C virus (HCV) infection. Anti-HCV antibodies were detectable in 3% of children in Upper Egypt. Our aim was to evaluate the efficacy of ledipasvir/sofosbuvir for chronic HCV genotype 4 in adolescents with/without hematological disorders and to determine the effect of sustained virological response (SVR) on liver stiffness. Methods Sixty-five adolescents were recruited. There were 3 patient groups: group 1, 44 treatment-naive without hematological disorders; group 2, 6 previously treated; and group 3, 15 treatment-naive with hematological disorders. All patients received sofosbuvir 400 mg/ledipasvir 90 mg per day for 12 weeks. Serum HCV RNA levels were measured before treatment, at week 12, and at 12 weeks after the end of treatment (SVR12). Liver stiffness and the aspartate aminotransferase–platelet ratio index (APRI) score were estimated at baseline and at SVR12. Results SVR12 was 100%. At SVR12, there was a significant improvement in liver stiffness in all groups. The APRI score showed significant improvements in groups 1 and 3 (P &lt; .001 and P = .004, respectively). The treatment was well tolerated, with minimal and self-limited side effects. Conclusions Treatment of chronic HCV in adolescents using ledipasvir/sofosbuvir was effective, with a cure rate (at SVR12) of 100%. Significant improvement in liver stiffness was found in all groups.

scholarly journals Insulin-like Growth Factor Initiates Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients through Induction of Long Non-coding Ribonucleic Acids AF085935

2021 ◽  
Vol 9 (A) ◽  
pp. 222-228
Author(s):  
Abeer Mostafa ◽  
Noha El-Sayed Ibrahim ◽  
Dina Sabry ◽  
Wael Fathy ◽  
Amany Y. Elkazaz
Keyword(s):  
Diagnostic Marker ◽  
Healthy Individuals ◽  
Ribonucleic Acids ◽  
Key Word ◽  
Chronic Hepatitis C Virus ◽  
Chronic Hcv Infection ◽  
Group 3 ◽  
Group 2 ◽  
Chronic Hcv ◽  
Group 1

Abstract HCV is the most commonly occurring hepatic infection worldwide.  Chronic HCV infection usually complicated with cirrhosis and even HCC with significant morbidity and mortality. The aim of this study to clarify the molecular mechanism by which HCV can induce HCC and identify a new diagnostic marker for early detection of HCC. Methods: 180 participating subject were divided in to three groups. Group 1: 60 healthy individuals (controls).  Group 2: 60 HCV infected patients. Group 3:  60 HCV patients developed HCC. Serum IGF, FOXO and LncRNA AF085935 were evaluated. Results:  Serum IGF was significantly elevated in HCV and HCC patients, while FOXO and LncRNA AF085935 were significantly up regulated in HCC. IGF significantly correlated with and LncRNA AF085935. Conclusion:  HCV can induce IGF with subsequent induction of   LncRNA AF085935 and FOXO. Key word: HCV, HCC, IGF, FOXO and LncRNA AF085935.

scholarly journals Antibodies against non-structural c100/3 and structural core antigen of hepatitis C virus (HCV) in hemodialysis patients

1993 ◽  
Vol 35 (4) ◽  
pp. 315-321 ◽  
Author(s):  
C.F.T. Yoshida ◽  
Y. Takahashi ◽  
B.O.M. Vanderborght ◽  
C.D. Rouzere ◽  
M.S. França ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Blood Transfusion ◽  
Core Protein ◽  
Hemodialysis Patients ◽  
Core Antigen ◽  
Prevalence Rates ◽  
High Prevalence ◽  
Group 2 ◽  
Group 1

Two groups of patients undergoing hemodialysis (HD) maintenance were evaluated for their antibody response to non-structural c100/3 protein and structural core protein of hepatitis C virus (HCV). Forty-six patients (Group 1) never presented liver abnormalities during HD treatment, while 52 patients (Group 2) had either current or prior liver enzyme elevations. Prevalence rates of 32.6% and 41.3% were found for anti-c100/3 and anti-HCV core antibodies, respectively, in patients with silent infections (Group 1). The rate of anti-c100/3 in patients of Group 2 was 71.15% and reached 86.5% for anti-HCV core antibodies. The recognition of anti-c100/3 and anti-core antibodies was significantly higher in Group 2 than in Group 1. A line immunoassay composed of structural and non-structural peptides was used as a confirmation assay. HBV infection, measured by the presence of anti-HBc antibodies, was observed in 39.8% of the patients. Six were HBsAg chronic carriers and 13 had naturally acquired anti-HBs antibodies. The duration of HD treatment was correlated with anti-HCV positivity. A high prevalence of 96.7% (Group 2) was found in patients who underwent more than 5 years of treatment. Our results suggest that anti-HCV core ELISA is more accurate for detecting HCV infection than anti-c100/3. Although the risk associated with the duration of HD treatment and blood transfusion was high, additional factors such as a significant non-transfusional spread of HCV seems to play a role as well. The identification of infective patients by more sensitive methods for HCV genome detection should help to control the transmission of HCV in the unit under study.

Study of IL28B gene variation as a predictor of response to directly acting antiviral therapy in hepatic transplantation hepatitis C Egyptian patients

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
H M Badawy ◽  
S S Taha ◽  
Y O Abdelrahman ◽  
S H Gadallah ◽  
R Samir ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Il28b Genotype ◽  
Donor Liver Transplantation ◽  
Gene Variation ◽  
Significant Difference ◽  
Group 2 ◽  
Group B ◽  
Group 1

Abstract Background IL28B gene polymorphisms are associated with the response to antiviral therapy in hepatitis C patients in the non-transplant setting. Objective To determine the prevalence and impact on clinical outcomes of donor and recipient IL28B genotypes among liver transplant recipients receiving directly acting antiviral therapy compared to those of HCV non-transplant patients. Patient and Methods This study included 60 patients divided into 2 groups: group 1 included 30 patients subjected to living donor liver transplantation and group 2 included 30 patients of HCV infection. Each group was subdivided into group A and group B according to the regimen of directly acting antiviral therapy (sofosbuvir-ledibasvir, sofosbuvir-daclatasvir). Liver transplantation was done between January 2016 and April 2018. Genotyping of the polymorphism was performed on DNA collected from all donors and recipients in group 1 before and after liver transplantation and also collected from all patients of group 2. Sustained virological response was found in 28 patients in group 1 (transplanted group) and 29 patients in group 2 (non-transplanted group) with no significant difference. Results No significant difference also was found in both groups according to the type of regimen. Also the type of genotype CC, CT and TT of IL28B in donors and recipients were not significantly associated or affecting the results of SVR in both groups of patients. Conclusion Our results support no role of recipient IL28B genotype in the response to directly acting antiviral drugs for hepatitis C recurrence. Interestingly, donor genotype seems not to influence the response pattern in recipients who have different IL28B genotype.

Protective role of Salvia miltiorrhiza Polysaccharides on Florfenicol Induced Oxidative and Apoptotic Injury of Liver in Broilers

2021 ◽  
Author(s):  
Xiao Wang ◽  
Yuqing Cui ◽  
Chao Han ◽  
Yumeng Geng ◽  
Di Zhang ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Liver Injury ◽  
Protein Expression ◽  
Liver Tissue ◽  
Salvia Miltiorrhiza ◽  
Protective Role ◽  
Heme Oxygenase 1 ◽  
Related Factor ◽  
Mrna And Protein Expression ◽  
Liver Tissues

Abstract Salvia miltiorrhiza Polysaccharides (SMPs) can alleviate liver injury in mice, but there are few reports on liver injury of broilers, especially the liver injury caused by antibiotics. To explore the hepatoprotective effects of SMPs against florfenicol (FFC) induced broilers liver injury, the broilers were treated with FFC and SMPs. The results showed SMPs could significantly inhibit the decrease of weight gain and the increase of liver index induced by FFC (P < 0.05). SMPs could significantly reduce the contents of Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) in serum and the malondialdehyde (MDA), nitric oxide (NO) and inducible nitric oxide synthase (iNOS) in liver tissues (P < 0.05), also significantly increased the content of total protein (TP) in serum and superoxide dismutase (SOD), catalase (CAT) in liver tissues (P < 0.05). QPCR and western bolt results showed that SMPs significantly increased the mRNA and protein expression of cytochrome P4501A1 (CYP1A1), cytochrome P4502H1 (CYP2H1), nuclear factor-erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1) and NAD(P)H dehydrogenase quinone-1 (NQO-1) in liver tissue, also significantly reduced the rate of hepatocyte apoptosis and the mRNA and protein expression of p53, cytochrome-C (CytC), caspase-3 in liver tissue (P < 0.05). The results demonstrated that SMPs can inhibit the oxidative stress in hepatocytes by regulating the related proteins in Nrf2 pathway, thereby reducing the apoptosis of hepatocytes, and protecting liver injury.

Нemocoagulation parameters in extensive liver resections

2021 ◽  
Author(s):  
Г.Э. Черкасов ◽  
И.Н. Соловьева ◽  
Н.Н. Багмет
Keyword(s):  
Blood Loss ◽  
Liver Tissue ◽  
International Normalized Ratio ◽  
Fresh Frozen Plasma ◽  
Postoperative Blood Loss ◽  
Control Group ◽  
Reference Ranges ◽  
Affecting Factors ◽  
Group 2 ◽  
Group 1

Введение. Нормализация параметров гемостаза после обширной резекции печени является профилактикой послеоперационной кровопотери, печеночной недостаточности и других осложнений. Цель исследования: проанализировать стандартные показатели гемостаза при обширной резекции печени (ОРП) и оценить влияющие на них факторы: характер заболевания, объем интраоперационной кровопотери, объем использованных гемокомпонентов. Материалы и методы. Обследовано 374 пациента, оперированных по поводу доброкачественных и злокачественных образований печени с 2000 по 2019 гг. Сформировано 2 группы: 93 пациента, оперированные в 2000–2006 гг. (группа 1), и 281 пациент, оперированные в 2007–2019 гг. (группа 2), когда использовали новые кровесберегающие технологии выделения и резекции печеночной ткани; в группу контроля вошли 89 соматически здоровых родственных доноров печени. До операции и в 1-е, 3-и и 7-е сутки послеоперационного периода изучены стандартные показатели плазменного гемостаза: фибриноген, активированное частичное тромбопластиновое время, международное нормализованное отношение и содержание тромбоцитов. Контролировали объем кровопотери и расход донорских гемокомпонентов. Результаты. Средний объем кровопотери в 2000–2006 гг. был в 1,8 раза больше, чем в последующие годы. Соответственно, объем перелитой эритромассы в группе 1 был выше в 2,8 раза, свежезамороженной плазмы — в 1,8 раза по сравнению с группой 2. Показатели гемостазиограммы до операции у всех больных были в референсных пределах. Критических нарушений гемокоагуляции после операций ОРП не наблюдалось. Отмечена некоторая тенденция к гипокоагуляции, максимально прослеживаемая у больных группы 1. Сохранение эффективной гемокоагуляции и значений гемоглобина было достигнуто адекватной гемотрансфузионной заместительной терапией. Заключение. На объем кровопотери при ОРП с высокой степенью значимости влияют метод диссекции ткани печени, маневр Прингла и характер новообразования. В свою очередь, параметры гемостаза зависят от величины кровопотери и адекватности ее замещения донорскими гемокомпонентами. Background. Normalization of hemostasis parameters after extensive liver resection (ELR) is a prevention of postoperative blood loss, liver failure and other complications. Objectives: to analyze the standard hemostasis parameters in ELR and to assess the affecting factors: the nature of the disease, the volume of intraoperative blood loss, the volume of used hemocomponents. Patients/Methods. We observed 374 patients operated on for benign and malignant liver formations for 20 years. Since 2006, blood-saving technologies have been used for isolation and resection of liver tissue. We compared 93 patients ope rated on in 2000–2006 (group 1), 281 patients operated on in 2007–2019 (group 2), and 89 healthy liver donors (control group). Standard parameters of plasma hemostasis — fibrinogen level, activated partial thromboplastin time, international normalized ratio and platelet count before surgery and on the 1st, 3rd and 7th days after surgery were studied. We controlled the volume of blood loss and the consumption of donor hemocomponents. Results. The average volume of blood loss in 2000–2006 was 1.8 times higher than in subsequent years. Accordingly, the volume of transfused erythromass in group 1 was 2.8 times higher, and the volume of transfused fresh frozen plasma was 1.8 times higher, than in group 2. Almost all hemostasiogram parameters before surgery in all patients were within the reference ranges. Critical coagulation disorders after ELR were not observed. A certain tendency towards hypocoagulation was noted that was maximally traced in patients of group 1. Maintaining effective hemocoagulation and hemoglobin values was achieved by adequate hemotransfusion replacement therapy. Conclusions. The method of liver tissue dissection, Pringle’s maneuver, and the nature of the neoplasm significantly affect the volume of blood loss in ELR. In turn, hemostasis parameters depend on the amount of blood loss and the adequacy of its replacement with donor hemocomponents.

scholarly journals Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
M. Ghabril ◽  
R. C. Dickson ◽  
M. Krishna ◽  
R. Lloyd ◽  
J. Aranda-Michel ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Treatment Duration ◽  
Sustained Viral Response ◽  
Hcv Rna ◽  
Undetectable Serum ◽  
Total Treatment ◽  
Similar Patient ◽  
Group 2 ◽  
Hepatitis C Rna ◽  
Group 1

Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with an end of treatment response. HCV RNA can be detected in liver tissue by in situ hybridization (ISH).Aim. To determine if HCV nondetectability in liver allografts by ISH can predict SVR in patients who cleared virus serologically on treatment.Methods. Twenty five patients with undetectable serum HCV on Interferon/Ribavirin therapy for HCV recurrence post liver transplant (LT) were studied. All had biopsies at 4 months post LT (baseline) and follow up with HCV ISH analysis performed.Results. 10 were ISH positive (group 1); 15 were ISH negative (group 2). Groups 1 and 2 had similar patient, donor, and viral characteristics at LT, as well as treatment duration at the time of the ISH assayed liver biopsy (13±16versus10±4monthsP= .24). However, group 1 had longer total treatment duration (24±10versus14±5months,P= .001). Eight (80%) group 1 and 9 (60%) group 2 patients achieved SVR. Mean grade and stage (modified Ishak score) were similar at 4 months, however, group 1 had higher grade (3±1.7versus1.6±1.3,P= .039) and stage (1.4±1.4versus0.5±0.6,P= .084) on the ISH assayed biopsy, after similar post LT intervals (23±10versus24±12months,P= .91).Conclusion. Allograft HCV ISH nondetectability does not predict SVR in treatment responsive HCV recurrence, but is associated with less severe histologic disease.

scholarly journals Validity of Autotaxin as a Novel Diagnostic Marker for Liver Fibrosis in Egyptian Chronic HCV Patients

2013 ◽  
Vol 1 (1) ◽  
pp. 21-26 ◽  
Author(s):  
Wafaa M. Ezzat ◽  
Halla M. Ragab ◽  
Nabila Abd El Maksoud ◽  
Nour A. Abdulla ◽  
Yasser A. Elhosary
Keyword(s):  
Liver Fibrosis ◽  
Diagnostic Marker ◽  
Fibrosis Score ◽  
Laboratory Assessment ◽  
Mean Values ◽  
Significant Difference ◽  
The Mean ◽  
Group 2 ◽  
Chronic Hcv ◽  
Group 1

We aimed to detect the validity of serum ATX as a diagnostic marker for liver fibrosis. Forty-eight males and 16 females were enrolled in the current study. Their ages ranged from 29-57 years with mean of 45.09, all were chronically HCV infected. Laboratory assessment was done for all subjects in form of complete blood picture; liver function test; lipid profile and serum detection of ATX. Patients were grouped according to the stage of fibrosis into group 1: fibrosis score 0, 1, 2, 3; group 2: fibrosis score: 4, 5, 6.The mean values of ATX in all studied patients with chronic HCV infection was 63.02 ± 36.29 while that of healthy controls was 65.31 ± 12.24 without any significant difference. Surprisingly, mean values of ATX were higher among patients with group 1 but it did not reach the significant level. In each group of them, the differences between mean values of ATX among different grades of liver fibrosis were insignificant. It was also noticed that the mean values of ATX were higher among men than in women .It was concluded that Autotoxin might not be used as a useful diagnostic marker for liver fibrosis in Egyptian chronic HCV patients.

scholarly journals Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication

2020 ◽  
Vol 11 (1) ◽  
pp. 26-37
Author(s):  
E. A. Nabatchikova ◽  
D. T. Abdurakhmanov ◽  
E. N. Nikulkina ◽  
T. P. Rozina ◽  
E. L. Tanaschuk ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Risk Factor ◽  
Hepatitis C ◽  
Independent Risk Factor ◽  
Transient Elastography ◽  
Albumin Level ◽  
Fibrosis Regression ◽  
Cirrhotic Patients ◽  
Group 2 ◽  
Group 1

Direct-acting antivirals (DAAs) therapy is associated with fibrosis regression in patients with hepatitis C virus liver cirrhosis.Aim. To study the dynamic of liver fibrosis in cirrhotic patients with a DAAs-induced sustained virological response (SVR).Materials and methods. The retrospective cohort study included 80 cirrhotic patients (male — 43%, median age 54 years). Liver stiffness (LS) was measured by transient elastography before treatment and after SVR. Patients with LS improvement ≥30% were included in group 1, other patients — in group 2. Clinical, laboratory and instrumental parameters were assessed. Independent risk factors for the absence of LS improvement ≥30% were determined by binary logistic regression with the definition of odds ration (OR) and 95% confidence interval (CI).Results. LS reduced from 21.35 (15.2; 27.7) to 13.5 [10.1; 20.0] kPa (p < 0.001), the median reduction was 5.1 [2.6; 11.0] kPa. Regression of fibrosis from F4 to F2 and F3 stages was observed in 16 (20%) and 19 (24%) of cases, respectively. Overall, 36 patients were included in group 1, 44 patients — in group 2. Platelet counts increased in group 1 compared to group 2 by 24.5% vs 5.2% (p = 0.014), a disappearance or reducing the size of esophageal varices were observed in 72% vs. 35% of cases (p = 0.035). Significant differences in ALT, AST, albumin, prothrombin time dynamics were not observed. Baseline albumin level ≤35 g/l is an independent risk factor for the absence of significant improvement of LS: OR 6.7 (95% CI 1.7–25.9, p = 0.006).Conclusion. SVR leads to fibrosis regression to F2-F3 stages in 44% of patients. Baseline albumin level ≤35 g/l is an independent risk factor for the absence of significant improvement of LS.

Sign in / Sign up

Export Citation Format

Share Document